Vtama in Psoriasis Patients Being Treated With Biologics.

• Status: Completed
• Trial end date: 2023-10-18
• Target enrollment: 0
• Participant gender: All

Summary

Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Criteria

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;

2. Diagnosis of chronic plaque-type

3. Patient with ≥3% BSA

4. Patient has been treated with biologic for a minimum of 24 weeks

5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion Criteria:

1. ≤3% BSA

2. Patient not receiving biologic agent, or receiving biologic agent <24weeks